Biologists, chemists, clinicians from Harvard, Stanford, University of Washington, the Scripps Research Institute, and Massachusetts General
Hospital partner with top investor groups Technology bypasses current debate on ethical use of embryonic stem cells by using pharmaceutical medicines to modulate stem cells inside the body
and via the use of 'reprogrammed' adult stem cells
SEATTLE, Nov. 29 /PRNewswire/ -- A group of the nation's most respected leaders in stem cell biology today announced formation of Fate Therapeutics, a new biotechnology company developing drugs to control cell fate. Fate will harness the healing power of adult stem cells by using small molecule drugs to modulate cells in vivo (in the body) and by reprogramming mature adult cells into stem cells.
"Fate's approach is the dawn of a new day in medicine," said Dr. Ben Shapiro, retired Executive Vice President of Worldwide Basic Research, Merck Research Laboratories, and a member of Fate's Science Advisory Board.
"Revolutionary advances in stem cell research have shifted the entire debate. We are proving that adult stem cell proliferation and differentiation can be modulated in the human body, and we now have the ability to induce pluripotent stem cells from adult human tissue rather than relying on the use of stem cells derived from embryos."
The company expects to have a lead adult stem cell modulating drug, in a cancer-related indication, enter the clinic in 2008.
Fate Therapeutics' revolutionary platform is two-fold
The Fate platform focuses on both regenerative and reprogramming
medicine. The Fate regenerative medicine platform involves developing drugs
that awaken adult stem cells in the body to repair damaged cells and
tissues. The Fate reprogramming medicine platform involves developing drugs
to reprogram mature adult cells into stem cells which when differentiated
can become healthy heart, bone, brain o
|SOURCE Fate Therapeutics|
Copyright©2007 PR Newswire.
All rights reserved